Timo Minssen

Timo Minssen is Professor of Law at the University of Copenhagen (UCPH) and the Founding Director of UCPH's Center for Advanced Studies in Bioscience Innovation Law (CeBIL). He also holds affiliations as an LML Research Affiliate at the University of Cambridge and an Inter-CeBIL Research Affiliate at Harvard Law School's Petrie-Flom Centre. With extensive expertise in Intellectual Property, Competition, and Regulatory Law, Minssen focuses on the legal aspects of emerging health and life science technologies, including genome editing, big data, artificial intelligence, and quantum technology.

His educational background includes a German law degree (Staatsexamen) from Georg-August-University in Göttingen, and Swedish biotech & IPR related LL.M., LL.Lic., and LL.D. degrees from Lund University and Uppsala University. His PhD thesis on the patentability of biopharmaceutical technology in the US & Europe received the prestigious Swedish King Oscar award.

• 2024: TUM Global Visiting Professor, Technical University of Munich (Germany)
• 2016: Visiting Research Fellow, University of Cambridge (UK)
• 2014: Visiting Research Fellow, University of Oxford (UK)
• 2013-14: Visiting Scholar, Harvard Law School (US)
• 2012: LL.D. - Doctor of Laws (Swedish "juris doktor"), EU/US patent law, Lund University, Sweden

Minssen's research spans AI & Big Data in Health & Life Sciences, Sustainable and responsible innovation & tech transfer, Pharmaceutical-, Life Science- & Biotech Law, Comparative European & US Patent Law, Intellectual Property Law & Open Innovation, and EU Competition- & US Antitrust Law. His work addresses legal issues throughout the lifecycle of health and life science products and processes, from R&D regulation to technology transfer and commercialization.

His extensive publication record includes 7 books and over 200 articles and book chapters published in leading journals such as Science, Nature Biotechnology, JAMA, and Harvard Business Review. His research has been featured in The Economist, Financial Times, and other major media outlets. Minssen's recent work shows a strong focus on AI regulation, quantum technology law, and data governance in health contexts, reflecting the evolving landscape of technology and law.

Scientific Awards and Recognition

• King Oscar award for best Jur. Dr. thesis (2014)
• Jorcks Fonds Forsknings Pris (Jorck's Foundation Research Prize) (2017)
• Awapatent Research Prize (2009)
• Max Planck Research Scholarship (2005)
• Visiting Scholar appointments at Harvard Law School, University of Oxford, and University of Cambridge
• Recipient of a Novo Nordisk Foundation Grant for a "Collaborative Research Program in Biomedical Innovation Law" (2018)

As an advisor, Minssen serves international organizations including the WHO, WIPO, and EU Commission. He has supervised numerous PhD students in areas including pharmaceutical law, biotechnology patents, and antimicrobial resistance. His current research projects include the Novo Nordisk Foundation's International Collaborative Bioscience Innovation & Law (Inter-CeBIL) Programme (50 million DKK), CLASSICA: EU Horizon Project on AI-assisted surgery, and AI@Care: Law and Ethics and Algorithmic Bias in Healthcare.

Minssen leads the Center for Advanced Studies in Bioscience Innovation Law (CeBIL), which serves as a hub for interdisciplinary research on the intersection of law, technology, and innovation in the health and life sciences. The center collaborates with institutions worldwide to address pressing legal challenges in emerging technologies.